Literature DB >> 23463460

[Granulomatous lung and systemic diseases].

A Prasse1, G Kayser, J Müller-Quernheim.   

Abstract

Granuloma formation occurs in the human body if there is a particle which persists in phagocytes and which the immune system cannot eliminate. The immune reaction of granuloma formation evolved in order to combat mycobacteria with the aim of localizing mycobacteria and to avoid spreading of mycobacteria throughout the body. Granulomatous lung diseases are often accompanied by severe, systemic inflammation. However, acute phase proteins may be only slightly elevated. The spectrum of granulomatous lung diseases is broad. Sarcoidosis is the most common granulomatous lung disease. To diagnose sarcoidosis, other infectious granulomatous lung diseases such as tuberculosis, atypical mycobacterial and fungal infection have to be ruled out. Pulmonary granuloma also evolve in the context of autoimmune diseases such as rheumatoid arthritis, granulomatosis with polyangiitis (GBA, Wegener's) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome). Furthermore, immunodeficiencies such as common variable immunodeficiency (CVID) and immune reconstitution syndrome in HIV can be associated with systemic granulomatous inflammation. Finally, occupational lung disease, particularly hypersensitivity pneumonitis, silicosis, hard metal lung, and chronic berylliosis are associated with pulmonary granuloma formation.

Entities:  

Mesh:

Year:  2013        PMID: 23463460     DOI: 10.1007/s00108-012-3187-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

2.  Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen.

Authors:  J Müller-Quernheim; K Kienast; M Held; S Pfeifer; U Costabel
Journal:  Eur Respir J       Date:  1999-11       Impact factor: 16.671

3.  Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.

Authors:  B Bradley; H M Branley; J J Egan; M S Greaves; D M Hansell; N K Harrison; N Hirani; R Hubbard; F Lake; A B Millar; W A H Wallace; A U Wells; M K Whyte; M L Wilsher
Journal:  Thorax       Date:  2008-09       Impact factor: 9.139

Review 4.  Update in tuberculosis and nontuberculous mycobacterial disease 2010.

Authors:  Wing Wai Yew; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  Am J Respir Crit Care Med       Date:  2011-07-15       Impact factor: 21.405

Review 5.  Steroid-sparing alternative treatments for sarcoidosis.

Authors:  R P Baughman; E E Lower
Journal:  Clin Chest Med       Date:  1997-12       Impact factor: 2.878

6.  Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.

Authors:  M K Park; H Babaali; L I Gilbert-McClain; M Stylianou; J Joo; J Moss; V C Manganiello
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2009-07       Impact factor: 0.670

7.  Genotype-corrected reference values for serum angiotensin-converting enzyme.

Authors:  H Biller; G Zissel; B Ruprecht; M Nauck; A Busse Grawitz; J Müller-Quernheim
Journal:  Eur Respir J       Date:  2006-12       Impact factor: 16.671

8.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Authors:  Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

Review 9.  [Epidemiology of tuberculosis in the world and in Germany].

Authors:  B Hauer; B Brodhun; D Altmann; M Brönnecke; R Loddenkemper; W Haas
Journal:  Pneumologie       Date:  2008-10-07

10.  European union standards for tuberculosis care.

Authors:  G B Migliori; J P Zellweger; I Abubakar; E Ibraim; J A Caminero; G De Vries; L D'Ambrosio; R Centis; G Sotgiu; O Menegale; K Kliiman; T Aksamit; D M Cirillo; M Danilovits; M Dara; K Dheda; A T Dinh-Xuan; H Kluge; C Lange; V Leimane; R Loddenkemper; L P Nicod; M C Raviglione; A Spanevello; V Ø Thomsen; M Villar; M Wanlin; J A Wedzicha; A Zumla; F Blasi; E Huitric; A Sandgren; D Manissero
Journal:  Eur Respir J       Date:  2012-04       Impact factor: 16.671

View more
  4 in total

Review 1.  [Differential diagnosis of granulomatous diseases].

Authors:  B Ehrenstein; C Brochhausen
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

2.  [Pulmonary granulomatous diseases and pulmonary manifestations of systemic granulomatous disease : Including tuberculosis and nontuberculous mycobacteriosis].

Authors:  S Piel; M Kreuter; F Herth; H-U Kauczor; C-P Heußel
Journal:  Radiologe       Date:  2016-10       Impact factor: 0.635

Review 3. 

Authors:  Stella Piel; Michael Kreuter; Felix Herth; Hans-Ulrich Kauczor; Claus Peter Heußel
Journal:  Pneumo News       Date:  2017-02-22

Review 4.  [Clinical pathology of granulomatous inflammation : With special emphasis on the lungs and central nervous system].

Authors:  C Tóth
Journal:  Radiologe       Date:  2016-10       Impact factor: 0.635

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.